Terms: = Lung cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Treatment
143 results:
1. Effective Differences between 2D and 3D Planned Brachytherapy in lung cancer: An Institutional Retrospective Study.
Lalić N; Bojović M; Ivanov O; Ličina J; Popević S; Stjepanović M; Bursać D; Lalić I; Milić R; Tomić S; Parapid B; Anđelković A
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541177
[No Abstract] [Full Text] [Related]
2. NPAS2 dampens chemo-sensitivity of lung adenocarcinoma cells by enhancing DNA damage repair.
Zhang Y; Chen Y; Huang W; Zhou Y; Wang Y; Fu K; Zhuang W
Cell Death Dis; 2024 Jan; 15(1):101. PubMed ID: 38291048
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China.
Ren M; Cai X; Jia L; Bai Q; Zhu X; Hu X; Wang Q; Luo Z; Zhou X
BMC Cancer; 2023 Dec; 23(1):1175. PubMed ID: 38041048
[TBL] [Abstract] [Full Text] [Related]
4. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
5. A two-center experience: The impact of COVID-19 on two brachytherapy programs in Ontario - virtual care, service suspension and radiation therapy workflow.
Chan K; Timotin E; Chung P; Han K; Milosevic M; Schnarr K; Sur R; Bosche J; Harnett N
J Med Imaging Radiat Sci; 2023 Sep; 54(3):436-445. PubMed ID: 37357051
[TBL] [Abstract] [Full Text] [Related]
6. A case report of pulmonary hepatoid adenocarcinoma: promoting standardized diagnosis and treatment of the rare disease.
Xu K; Gao J; Feng L; Fang Y; Tang X
Front Immunol; 2023; 14():1203876. PubMed ID: 37292208
[TBL] [Abstract] [Full Text] [Related]
7. High-dose-rate brachytherapy for airway malignancy a single institution experience.
Siddiqui Z; Falkson C; Hopman W; Mahmud A
Brachytherapy; 2023; 22(4):542-546. PubMed ID: 37217415
[TBL] [Abstract] [Full Text] [Related]
8. Metastases to the kidney from primary lung cancer : clinicopathological analysis of six cases in a single center.
Lian H; Pan X; Hong B; Min J; Huang F
Diagn Pathol; 2023 May; 18(1):60. PubMed ID: 37161448
[TBL] [Abstract] [Full Text] [Related]
9. Risk Factors for Operation Complications of High Dose Rate 3-Dimensional Interstitial Brachytherapy for lung cancer.
Li X; Zhou H; Mou K; Zheng Y; Li H; Ren P; Ye H; Lin S; Pang H; Wu J; Xiang L
Clin Lung Cancer; 2023 Jul; 24(5):e187-e194. PubMed ID: 37149479
[TBL] [Abstract] [Full Text] [Related]
10. A review article on the dosimetry in intraluminal hdr brachytherapy of lung carcinoma.
Kant R; Gupta M; Bisht J; Nautiyal V; Kumar V; Dobhal R; Ahmed M; Saini S
J Cancer Res Ther; 2023 Apr; 19(Supplement):S36-S40. PubMed ID: 37147980
[TBL] [Abstract] [Full Text] [Related]
11. High dose rate endoluminal brachytherapy in the treatment of endobronchial lesions - experience of a single institution and literature review.
Macías-Lozano MJ; Díaz-Díaz V; Sayago-Gil S; García-Polo C; Jaén-Olasolo J
Support Care Cancer; 2023 Apr; 31(5):260. PubMed ID: 37052737
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathological Features and Prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients.
Wang S; Li W; Li S; Liu X; Zhang L; Hao C; Meng W; Zhao W; Tong Z
Int J Surg Pathol; 2023 Sep; 31(6):1075-1084. PubMed ID: 36803140
[No Abstract] [Full Text] [Related]
13. Implantation of computed tomography-guided high-dose-rate 192Ir brachytherapy in oldest old patients with advanced non-small cell lung cancer: A case report and literature review.
Cui R; Wang XL; Cao J
Medicine (Baltimore); 2022 Dec; 101(52):e32450. PubMed ID: 36595988
[TBL] [Abstract] [Full Text] [Related]
14. Percutaneous high-dose-rate interstitial brachytherapy for non-resectable, chemo resistant malignant lesion of lung and liver.
Yadawa N; Shahi UP; Mandal A; Verma A; Kumari K; Aggrawal LM; Jaiswal I; Mourya A; Jaiswal AK; Srivastava P
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S807-S814. PubMed ID: 38384060
[TBL] [Abstract] [Full Text] [Related]
15. MicroRNA-449a Inhibits Triple Negative Breast cancer by Disturbing DNA Repair and Chromatid Separation.
Vajen B; Bhowmick R; Greiwe L; Schäffer V; Eilers M; Reinkens T; Stalke A; Schmidt G; Fiedler J; Thum T; DeLuca DS; Hickson ID; Schlegelberger B; Illig T; Skawran B
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563522
[TBL] [Abstract] [Full Text] [Related]
16. [Clinicopathological analysis of lung metastatic tumor].
Lou N; Niu YR; Yang F; Lu ZH
Zhonghua Bing Li Xue Za Zhi; 2021 Sep; 50(9):1039-1044. PubMed ID: 34496496
[No Abstract] [Full Text] [Related]
17. Palliative treatment with high-dose-rate endobronchial interventional radiotherapy (Brachytherapy) for lung cancer patients.
Soror T; Kovács G; Wecker S; Ismail M; Badakhshi H
Brachytherapy; 2021; 20(6):1269-1275. PubMed ID: 34429246
[TBL] [Abstract] [Full Text] [Related]
18. A review of dosimetric impact of implementation of model-based dose calculation algorithms (MBDCAs) for hdr brachytherapy.
Yousif YAM; Osman AFI; Halato MA
Phys Eng Sci Med; 2021 Sep; 44(3):871-886. PubMed ID: 34142317
[TBL] [Abstract] [Full Text] [Related]
19. Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation.
Yoon SM; Suh R; Abtin F; Moghanaki D; Genshaft S; Kamrava M; Drakaki A; Liu S; Venkat P; Lee A; Chang AJ
Radiat Oncol; 2021 Jun; 16(1):99. PubMed ID: 34098977
[TBL] [Abstract] [Full Text] [Related]
20. Poor prognosis of male triple-positive breast cancer patients: a propensity score matched SEER analysis and molecular portraits.
Wang B; Wang H; Zhao A; Zhang M; Yang J
BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
[TBL] [Abstract] [Full Text] [Related]
[Next]
